RxDoctor Payments Data

Robert Siegel, MD

Cardiovascular Disease · Los Angeles, CANPI 1073542338

Payments from drug & device makers

$240,577in general payments, 2019–2025

Across 41 payments — averaging $5867.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lantheus Medical Imaging, Inc.$152K
  • Kiniksa Pharmaceuticals, Ltd.$75K
  • Celltrion, Inc.$9K
  • Abbott$5K
  • Artivion, Inc.$115
  • E.r. Squibb & Sons, L.L.C.$24

What the payments were for

  • Consulting fees$7,18042%
  • Speaking & faculty fees$8,04047%
  • Travel & lodging$1,3098%
  • Food & beverage$4433%

General payments by program year

20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$240,577 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$201,948
Medicare patients
1,950
Services billed
3,551

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CamzyosMavacamten32$251,174
EliquisApixaban61$63,967
JardianceEmpagliflozin18$30,143
EntrestoSacubitril/Valsartan24$28,229
XareltoRivaroxaban12$23,141
Repatha SureclickEvolocumab32$21,162
Colchicine32$4,219
Icosapent Ethyl15$2,609
Rosuvastatin Calcium78$1,952
Nebivolol Hcl24$1,804
Metoprolol Succinate105$1,789
Atorvastatin Calcium105$1,389
Ezetimibe42$1,131
Amlodipine Besylate118$1,055
Losartan Potassium54$714

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Camzyos$24$251,17432 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →